Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Sørensen, Benny ^a   Spahn, Donat R ^b   Innerhofer, Petra ^c   Spannagl, Michael ^d   Rossaint, Rolf ^e  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BERIPLEX; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING INHIBITOR; COFACT; FRESH FROZEN PLASMA; OCTAPLEX; PROTHROMBIN; PROTHROMBIN COMPLEX; PROTHROMBINEX; RECOMBINANT BLOOD CLOTTING FACTOR 9; UMAN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; BLEEDING; CONCENTRATION (PARAMETERS); DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; HEMOPHILIA; HUMAN; INJURY; PATHOGENESIS; PERIOPERATIVE COMPLICATION; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOGENICITY; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 79953306391     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9311     Document Type: Review

References (55)

1. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007, 370:439-448. 10.1016/S0140-6736(07)61199-4, 17679021.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:160S-198S. 10.1378/chest.08-0670, 18574265.
3. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006, 132:277-285. 10.1111/j.1365-2141.2005.05856.x, 16409292.
4. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348:423-428. 10.1016/S0140-6736(96)01109-9, 8709780.
5. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, Kwasny H, Haertel S, Barthels M. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003, 15:15-20. 10.1097/00042737-200301000-00004, 12544689.
6. Coagulation Management in TraumaRelated Massive Bleeding. , http://www.oegari.at/arbeitsgruppe.asp?id=116
7. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. Management of bleeding following major trauma: a European guideline. Crit Care 2007, 11:R17. 10.1186/cc5686, 2151863, 17298665.
8. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, Locker GJ, Laczika K, Knapp S, Watzke H. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999, 25:1105-1110. 10.1007/s001340051019, 10551966.
9. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008, 62:1614-1622. 10.1111/j.1742-1241.2008.01859.x, 18691229.
10. Imberti D, Barillari G, Biasioli C, Bianchi M, Contino L, Duce R, D'Inca M, Mameli L, Pinna L, Ageno W. Prothrombin complex concentrates for urgent anticoagulation reversal in patients with intracranial haemorrhage. Pathophysiol Haemost Thromb 2008, 36:259-265. 10.1159/000252822, 19996636.
11. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991, 28:3-5.
12. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999, 95:S13-S17. 10.1016/S0049-3848(99)00079-1, 10499904.
13. Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol 1993, 30:36-40.
14. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008, 83:137-143. 10.1002/ajh.21046, 17729241.
15. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006, 4:967-970. 10.1111/j.1538-7836.2006.01815.x, 16689743.
16. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006, 118:313-320. 10.1016/j.thromres.2005.08.005, 16182346.
17. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002, 116:619-624. 10.1046/j.0007-1048.2001.03295.x, 11849221.
18. Pabinger-Fasching I. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res 2008, 122(Suppl 2):S19-S22. 10.1016/S0049-3848(08)70005-7, 18549908.
19. Bagot CN, Cregg R, Patel RK, Shariff A, Arya R. Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. Thromb Haemost 2007, 98:1141-1142.
20. Warren O, Simon B. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. Ann Emerg Med 2009, 53:758-761. 10.1016/j.annemergmed.2008.12.027, 19181420.
21. Innerhofer P. Perioperative management of coagulation. Hamostaseologie 2006, 26:S3-S14.
22. Kohler M, Hellstern P, Lechler E, Uberfuhr P, Muller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998, 80:399-402.
23. Hellstern P, Beeck H, Fellhauer A, Fischer A, Faller-Stockl B. Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group. Vox Sang 1997, 73:155-161. 10.1046/j.1423-0410.1997.7330155.x, 9358617.
24. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008, 12:R105. 10.1186/cc6987, 2575594, 18706082.
25. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care 2009, 13:R191. 10.1186/cc8186, 2811941, 19948037.
26. Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979, 54:1028-1038.
27. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulantactive phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982, 59:401-407.
28. Kusch M, Seitz R, Konig H. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes. Thromb Haemost 1998, 79:778-783.
29. Dusel CH, Grundmann C, Eich S, Seitz R, Konig H. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004, 15:405-411. 10.1097/01.mbc.0000114437.81125.2b, 15205589.
30. Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis 2002, 13:653-655. 10.1097/00001721-200210000-00012, 12439153.
31. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558. 10.1002/hep.20569, 15726661.
32. Allen GA, Wolberg AS, Oliver JA, Hoff man M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004, 2:402-413. 10.1111/j.1538-7933.2003.00617.x, 15009455.
33. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989, 62:788-791.
34. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008, 6:125-131. 10.1111/j.1538-7836.2007.02824.x, 17988231.
35. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation annotation. Br J Haematol 2001, 114:271-280. 10.1046/j.1365-2141.2001.02908.x, 11529844.
36. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007, 98:790-797.
37. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009, 49:1171-1177. 10.1111/j.1537-2995.2008.02080.x, 19210325.
38. Ageno W, Garcia D, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosetto A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol 2009, 84:584-588. 10.1002/ajh.21469, 19610020.
39. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004, 44:1774-1789. 10.1111/j.0041-1132.2004.04347.x, 15584994.
40. Siegenthaler MA, Schneider P, Vu DH, Tissot JD. Haemovigilance in a general university hospital: need for a more comprehensive classification and a codification of transfusion-related events. Vox Sang 2005, 88:22-30. 10.1111/j.1423-0410.2005.00559.x, 15663719.
41. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626. 10.1182/blood-2008-07-077370, 2962447, 18809775.
42. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004, 126:139-152. 10.1111/j.1365-2141.2004.04973.x, 15198745.
43. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004, 125:69-73. 10.1111/j.1365-2141.2004.04868.x, 15015971.
44. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000, 14:458-461. 10.1080/02688690050175265, 11198768.
45. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992, 23:972-977.
46. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
47. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37:1465-1470. 10.1161/01.STR.0000221786.81354.d6, 16675739.
48. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003, 14:469-477. 10.1097/00001721-200307000-00007, 12851533.
49. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006, 44:440-445. 10.1002/hep.21266, 16871542.
50. Romisch J, Bonik K, Muller HG. Comparative in vitro investigation of prothrombin complex concentrates. Semin Thromb Hemost 1998, 24:175-181. 10.1055/s-2007-995838, 9579640.
51. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer P. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007, 105:905-917. 10.1213/01.ane.0000280481.18570.27, 17898365.
52. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005, 11(Suppl 1):1-6. 10.1111/j.1365-2516.2005.01156.x, 16219042.
53. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005, 3:2039-2043. 10.1111/j.1538-7836.2005.01513.x, 1410193, 16102110.
54. World Federation of Hemophilia Registry of Clotting Factor Concentrates. , http://www.wfh.org/2/docs/Publications/Treatment_Products/Monographs/FF6_Registry_8th_2008.pdf
55. Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol 2010, 89:309-316. 10.1007/s00277-009-0830-7, 19787352.